CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.

[1]  M. Macek,et al.  Identification of 99% of CFTR gene mutations in Bulgarian‐, Bulgarian Turk‐, and Roma cystic fibrosis patients , 2019, Molecular genetics & genomic medicine.

[2]  P. Reix,et al.  Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles , 2019, Clinical Case Reports.

[3]  S. Donaldson,et al.  Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  G. Sawicki,et al.  Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. , 2015, American journal of respiratory and critical care medicine.

[5]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[6]  K. McCoy,et al.  Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation , 2015, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[7]  M. Higgins,et al.  Clinical drug‐drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P‐glycoprotein , 2015, Journal of clinical pharmacology.

[8]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[9]  P. Lee,et al.  Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[10]  M. Bellin,et al.  Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study , 2013, Pediatric diabetes.

[11]  N. Tustison,et al.  46 Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation , 2012 .

[12]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.